Black Hawk Acquisition

The existence and terms of the Vesicor business combination (closing, dilution, and PIPE structure) are the primary causal determinant of shareholder value; absent a close the SPAC will not generate operating upside. If the deal closes with modest redemptions and adequate PIPE, shareholders get exposure to Vesicor's upside; if it fails or is financed only after heavy dilution, the equity will likely underperform or revert to SPAC redemption outcomes.

Sponsor advances or PIPE commitments will be required to fund pre-close working capital and deal expenses because cash outside the trust is negligible. If sponsor/related parties provide timely funding, the SPAC can complete deal diligence and close; if they withhold funds, the SPAC risks inability to meet obligations or must abandon/renegotiate the transaction.

Operating cash demands (G&A, deal costs, post-close clinical financing) exceed interest income; unless financed externally the SPAC/combined entity will face cash shortfalls that impair the project. Sustained negative operating cash flow implies reliance on external financing; inability to obtain it forces deal abandonment or severe dilution.